Pancreatic Cancer Research

ResearcherKagawa UniversityNo recent work listed

Yasuyuki Suzuki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3138-9296; OpenAlex author ID A5041602945. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 2 papers

Papers 17

  1. P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with … Last author DOI 10.1002/jhbp.1286↗
  2. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adeno… Co-author DOI 10.1016/j.hpb.2022.10.004↗
  3. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiothe… Last author DOI 10.1002/jso.26854↗
  4. Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer. Last author DOI 10.1093/jjco/hyac074↗
  5. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002011↗
  6. Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer. Last author DOI 10.1177/0003134821998671↗
  7. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.09.006↗
  8. Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer. Co-author DOI 10.1038/s41598-021-86152-y↗
  9. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrosp… Co-author DOI 10.1159/000517244↗
  10. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable p… Last author DOI 10.1186/s12876-020-01566-8↗
  11. Is surgery after neoadjuvant chemoradiotherapy feasible for elderly patients with resectable or borderline resectable pancreatic ductal adenocarcinoma? Last author DOI 10.21203/rs.2.21112/v1↗
  12. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvan… Last author DOI 10.1186/s12893-019-0644-z↗
  13. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Last author DOI 10.1093/jjco/hyy033↗
  14. MicroRNA profiles during galectin-9-induced apoptosis of pancreatic cancer cells. Co-author DOI 10.3892/ol.2017.7316↗
  15. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic … Last author DOI 10.1245/s10434-017-5921-4↗
  16. (Pro)renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep08854↗
  17. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic… Co-author DOI 10.1097/sla.0b013e3182827a65↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keiichi Okano · 16 shared papers, 2013–2023 · strength 1.82
  2. Minoru Oshima · 13 shared papers, 2013–2023 · strength 1.52
  3. Tsutomu Masaki · 13 shared papers, 2015–2023 · strength 1.47
  4. Hironobu Suto · 11 shared papers, 2017–2023 · strength 1.36
  5. Toru Shibata · 7 shared papers, 2017–2023 · strength 0.83
  6. Shigeo Takahashi · 6 shared papers, 2017–2023 · strength 0.73
  7. Akihito Tsuji · 3 shared papers, 2018–2022 · strength 0.35
  8. Ayaka Shimomura · 2 shared papers, 2021–2022 · strength 0.22
  9. Keiko Yamakawa · 2 shared papers, 2021 · strength 0.22
  10. Yoko Matsuda · 2 shared papers, 2021 · strength 0.22
  11. Juanjuan Ye · 2 shared papers, 2021 · strength 0.22
  12. Motohiro Kojima · 2 shared papers, 2021 · strength 0.22
  13. Masanao Yokohira · 2 shared papers, 2021 · strength 0.22
  14. Mina Nagao · 2 shared papers, 2018–2022 · strength 0.19
  15. Kotone Hayuka · 1 shared paper, 2021 · strength 0.14
  16. Yukiko Wada · 1 shared paper, 2022 · strength 0.12
  17. Kenichi Hirabayashi · 1 shared paper, 2021 · strength 0.12
  18. Ai Kameyama · 1 shared paper, 2021 · strength 0.10
  19. Mutsuo Furihata · 1 shared paper, 2021 · strength 0.10
  20. Mari A. Mino-Kenudson · 1 shared paper, 2021 · strength 0.10
  21. Chiharu Tanaka · 1 shared paper, 2021 · strength 0.10
  22. Shinichi Yachida · 2 shared papers, 2013–2015 · strength 0.08
  23. Ryoichi Okura · 1 shared paper, 2018 · strength 0.06
  24. Kiyohito Kato · 1 shared paper, 2018 · strength 0.06
  25. Akira Nishiyama · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.